Apollo introduces Zap-X for non-invasive brain tumour treatment

BL New Delhi Bureau Updated - March 08, 2024 at 08:23 PM.

Apollo Hospitals Group, India’s largest vertically integrated healthcare provider, on Friday unveiled the ZAP-X Gyroscopic Radiosurgery Platform, used in carrying out non-invasion brain tumour treatment.

Also read: Apollo Hospital’s pharmacy business to touch ₹10,000 crore in revenue this year 

ZAP-X offers a non-invasive, pain-free alternative with sessions lasting just 30 minutes, the hospital said in a statement adding that the technology has high precision with minimal radiation exposure.

Unlike conventional methods, ZAP-X utilizes a self-shielded, gyroscopic linear accelerator design accurately focussing radiation on the intended tumour.

“For more than four decades, Apollo Hospitals has been at the forefront of healthcare. ZAP -X allows for non-invasive, pain-free sessions lasting 30 minutes, with minimal exposure to radiation,” Dr Prathap Chandra Reddy, Founder Chairman, Apollo Hospitals Group.

ZAP-X, it was claimed has a high success, ensuring effective control and relief for various conditions with minimal side effects. It achieves over 95 per cent control rate in 10 years with minimal facial or trigeminal side effects, the healthcare provider said.

ZAP-X shows an exceptional 99.4 per cent control rate in 5 years for small, defined tumours, Apollo mentioned.

Published on March 8, 2024 14:53

This is a Premium article available exclusively to our subscribers.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

You have reached your free article limit.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

You have reached your free article limit.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

TheHindu Businessline operates by its editorial values to provide you quality journalism.

This is your last free article.